Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED · Alpha
██.█% Sign up free to reveal

Erasca, Inc. (ERAS) AI Forecast

Our AI ranks Erasca, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$ERAS Bullish Signal Full forecast available

Erasca, Inc. (ERAS) Stock Forecast Sept. 24, 2026


Erasca, Inc. (ERAS) AI Stock Price Forecast & Investment Analysis

Erasca, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Erasca, Inc. (ERAS) - Comprehensive Stock Analysis & Investment Research

Deep dive into Erasca, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 24, 2026 (UTC)

Erasca, Inc. Investment Summary

When evaluating whether Erasca, Inc. (ERAS) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Erasca, Inc. (ERAS) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $5 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Erasca, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Erasca, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Erasca, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Erasca, Inc.

Sign Up Free
Corporate Identity

Erasca, Inc. (Stock Symbol: ERAS) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Erasca, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Erasca, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Erasca, Inc....

Unlock Full Company Profile

Get complete details about Erasca, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Erasca, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Erasca, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Erasca, Inc....

Unlock Financial Analysis

Get complete financial metrics for Erasca, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Erasca, Inc.'s AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Erasca, Inc. strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Erasca, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-98 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Financial Strength & Leverage

Current ratio of 8.29 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Erasca, Inc. (ERAS) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Erasca, Inc. stock analysis. Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.

Deep dive into Erasca, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Erasca, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Erasca, Inc.:

P/B Ratio 14.03x
Market Cap $5.08B
EPS $-0.46
Book Value/Share $1.03
FCF/Share $-0.28
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Erasca, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Erasca, Inc.:

ROIC -75.4%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Erasca, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Erasca, Inc.: A current ratio of 8.29 indicates strong liquidity.

Current Ratio 8.29x
D/E Ratio 0.20x
Financial Leverage 1.20x
Working Capital $245M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Erasca, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Erasca, Inc.: Free cash flow of $-98M indicates cash challenges that need attention.

Operating Cash Flow -$98M
Free Cash Flow -$98M
Capital Spending -$60K
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Erasca, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Erasca, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Erasca, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Erasca, Inc.:

Income Statement
Operating Income -$302M
R&D Expense $109M
Balance Sheet Highlights (USD millions)
Total Current Assets $278M (64.0% of assets)
Cash & Short-term Investments $43M (9.8% of assets)
Total Liabilities $73M (16.8% of assets)
Short-term Debt $32M (7.3% of assets)
Dividend & Shareholder Information
Shares Outstanding 350M

Latest Erasca, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Erasca, Inc. (ERAS) stock price and investment outlook.

📰 Loading...

Where ERAS sits on the market map

Explore the map →

Erasca, Inc. Industry Peers - Pharmaceutical Preparations

Companies classified under the same SEC industry code as Erasca, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
ERAS ██% $5.08B x 14.0x
LLY ██% $1.08T 40.6x 110.2x
JNJ ██% $648.67B 30.8x 7.6x
ONC ██% $539.52B x 104.3x
ABBV ██% $468.43B 74.2x x
MRK ██% $365.34B 115.1x 8.7x
NVS ██% $272.31B x x
GSK ██% $214.26B x x
ABT ██% $180.26B 28.6x 3.5x
PFE ██% $160.62B 37.1x 1.9x
VRTX ██% $130.87B 29.7x 6.5x
BMY ██% $125.63B 13.5x 5.6x
REGN ██% $82.55B 19.1x 2.6x
SNY ██% $50.80B x x
TEVA ██% $45.46B 64.3x 5.9x
ALNY ██% $33.40B x 24.7x
RPRX ██% $33.15B 40.7x 4.9x
ATHE ██% $32.40B x x
TAK ██% $29.93B x x
ZLAB ██% $29.68B x 48.9x
ZTS ██% $29.59B 11.3x 9.4x
ROIV ██% $26.60B x 6.3x
INSM ██% $25.84B x 34.1x
UTHR ██% $20.99B 16.0x 3.3x
VTRS ██% $19.66B x x
JAZZ ██% $15.25B 16.2x 3.2x
ASND ██% $14.30B x x
SMMT ██% $13.12B x 20.8x
BBIO ██% $12.96B x x
CORT ██% $12.81B x 18.2x
HCM ██% $12.54B x 10.1x
BMRN ██% $11.88B x 1.9x
KNSA ██% $11.87B x 19.6x
MDGL ██% $11.85B x 22.6x
ELAN ██% $11.17B x 1.7x
RDY ██% $10.34B x x
AXSM ██% $10.27B x 123.3x
ARWR ██% $9.33B x 20.1x
CYTK ██% $9.13B x x
PTGX ██% $8.98B x 10.7x
PRAX ██% $7.88B x 5.9x
SYRE ██% $7.77B x 7.1x
GPCR ██% $7.71B x 5.7x
ABVX ██% $7.39B x x
IONS ██% $7.30B x 16.6x
ALKS ██% $6.84B x 3.8x
LEGN ██% $6.82B x x
RYTM ██% $6.76B x 65.7x
BLRX ██% $6.68B x x
BLTE ██% $6.67B x 8.7x
AMRX ██% $6.32B x x
LQDA ██% $6.04B x 31.0x
LGND ██% $5.95B 30.2x 6.2x
MIRM ██% $5.80B x x
AMRN ██% $5.64B x 12.7x
TVTX ██% $5.64B x 230.0x
COGT ██% $5.45B x 10.2x
PTCT ██% $5.20B x x
DNTH ██% $5.07B x 4.3x
VKTX ██% $4.86B x 11.9x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Erasca, Inc. Stock Forecast

How accurate are Erasca, Inc. stock predictions?

A per-ticker accuracy statistic for ERAS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Erasca, Inc. stock price forecasts?

Our analysis considers Erasca, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Erasca, Inc. a good investment in 2026?

Based on our AI analysis, Erasca, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Erasca, Inc. forecasts updated?

Erasca, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 24, 2026.

Want a simpler view of Erasca, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...